Business Context and Reporting Period
Bionexus Gene Lab Corp, a Wyoming corporation, filed this Form 8-K on December 24, 2020, to report the entry into a Material Definitive Agreement. The company is based in Kuala Lumpur, Malaysia.
Key Financial Metrics
This filing does not provide financial metrics for Bionexus Gene Lab Corp itself. It discloses historical financial data for the target company, Chemrex Corporation Sdn. Bhd.:
- Chemrex Revenue (FY 2019): Approximately $15,636,064 USD (unaudited).
- Chemrex Net Profit (FY 2019): Approximately $308,083 USD (unaudited).
- Transaction Consideration: 68,487,261 shares of Bionexus common stock to be issued to Chemrex shareholders.
Material Changes
The primary material change is the acquisition of 100% of the issued and outstanding shares of Chemrex Corporation Sdn. Bhd., a Malaysian company specializing in the wholesale of chemicals and resins for industrial, medical, and equipment manufacturers. The transaction is scheduled to close on December 31, 2020.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure that the summary of the Share Exchange Agreement is qualified by the full agreement filed as Exhibit 10.5. No unusual items or contingencies were explicitly detailed in the text provided.
Investor Verification Checklist
- Verify the closing date of the transaction (scheduled for December 31, 2020) and confirm if it has occurred.
- Review the full Share Exchange Agreement (Exhibit 10.5) for customary terms, conditions, and representations not detailed in this summary.
- Confirm the dilution impact of issuing 68,487,261 new shares on existing shareholders.
- Validate the unaudited financial figures provided for Chemrex Corporation Sdn. Bhd. for the fiscal year ended December 31, 2019.